دورية أكاديمية
Hepatectomy versus systemic therapy for liver-limited BRAF V600E-mutated colorectal liver metastases: multicentre retrospective study.
| العنوان: | Hepatectomy versus systemic therapy for liver-limited BRAF V600E-mutated colorectal liver metastases: multicentre retrospective study. |
|---|---|
| المؤلفون: | Margonis GA; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Wang JJ; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Boerner T; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Moretto R; Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, Pisa, Italy., Buettner S; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Andreatos N; Department of General Surgery, Digestive Disease Institute, Cleveland Clinic, Cleveland, Ohio, USA., Gagnière J; Department of Digestive and Hepatobiliary Surgery-Liver Transplantation U1071 Inserm/Clermont-Auvergne University Hospital of Clermont-Ferrand, Clermont-Ferrand, France., Wagner D; Department of General Surgery, Medical University of Graz, Graz, Austria., Løes IM; Department of Clinical Science, University of Bergen, Department of Oncology, Haukeland University Hospital, Bergen, Norway., Bergamo F; Unit of Medical Oncology 1, Department of Oncology, Veneto Institute of Oncology, IRCCS, Padua, Italy., Pietrantonio F; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Scartozzi M; Medical Oncology, University Hospital of Cagliari, Cagliari, Italy., Spallanzani A; Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy., Vincenzi B; Department of Medical Oncology, Campus Bio-Medico, Università di Roma, Rome, Italy., Antoniou E; Third Department of Surgery, School of Medicine, National and Kapodistrian University of Athens, 'Attikon' University General Hospital, Athens, Greece., Pikoulis E; Third Department of Surgery, School of Medicine, National and Kapodistrian University of Athens, 'Attikon' University General Hospital, Athens, Greece., Sartore-Bianchi A; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy.; Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy.; Division of Clinical Research and Innovation, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Stasinos G; Technical Chamber of Greece, Athens, Greece., Sasaki K; Department of Surgery, Stanford University School of Medicine, Stanford, California, USA., Pawlik TM; Department of Surgery, Ohio State University Wexner Medical Center, Columbus, Ohio, USA., Orlandi A; Comprehensive Cancer Centre, Medical Oncology Unit, Fondazione Policlinico Universitario Agostino Gemelli-IRCCS, Rome, Italy., Pella N; Department of Oncology, ASUFC University Hospital of Udine, Udine, Italy., Fitschek F; Department of General Surgery, Medical University of Vienna, Vienna, Austria., Kaczirek K; Department of General Surgery, Medical University of Vienna, Vienna, Austria., Dupré A; Department of Surgery, Léon Bérard Cancer Centre Lyon, Lyon, France., Pozios I; Department of General and Visceral Surgery, Charité Campus Benjamin Franklin, Berlin, Germany., Beyer K; Department of General and Visceral Surgery, Charité Campus Benjamin Franklin, Berlin, Germany., Kornprat P; Department of General Surgery, Medical University of Graz, Graz, Austria., Aucejo FN; Department of General Surgery, Digestive Disease Institute, Cleveland Clinic, Cleveland, Ohio, USA., Burkhart R; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Weiss MJ; Northwell Health Cancer Institute, Zucker School of Medicine at Hofstra, New York, New York, USA., Lønning PE; Department of Clinical Science, University of Bergen, Department of Oncology, Haukeland University Hospital, Bergen, Norway., Poultsides G; Technical Chamber of Greece, Athens, Greece., Cremolini C; Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, Pisa, Italy., Kreis ME; Department of General and Visceral Surgery, Charité Campus Benjamin Franklin, Berlin, Germany., D'Angelica M; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA. |
| المصدر: | The British journal of surgery [Br J Surg] 2024 Jul 02; Vol. 111 (7). |
| نوع المنشور: | Journal Article; Multicenter Study; Observational Study; Comparative Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press on behalf of BJS Foundation Ltd Country of Publication: England NLM ID: 0372553 Publication Model: Print Cited Medium: Internet ISSN: 1365-2168 (Electronic) Linking ISSN: 00071323 NLM ISO Abbreviation: Br J Surg Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2021- : [Oxford] : Oxford University Press on behalf of BJS Foundation Ltd. Original Publication: [Bristol, England : Baltimore : John Wright & Sons ; Williams & Wilkins Co. |
| مواضيع طبية MeSH: | Liver Neoplasms*/secondary , Liver Neoplasms*/genetics , Liver Neoplasms*/surgery , Liver Neoplasms*/mortality , Hepatectomy*/methods , Colorectal Neoplasms*/genetics , Colorectal Neoplasms*/pathology , Proto-Oncogene Proteins B-raf*/genetics, Humans ; Male ; Female ; Retrospective Studies ; Middle Aged ; Aged ; Mutation ; Propensity Score ; Neoplasm Recurrence, Local/genetics ; Adult ; Treatment Outcome |
| مستخلص: | Background: To date, only two studies have compared the outcomes of patients with liver-limited BRAF V600E-mutated colorectal liver metastases (CRLMs) managed with resection versus systemic therapy alone, and these have reported contradictory findings. Methods: In this observational, international, multicentre study, patients with liver-limited BRAF V600E-mutated CRLMs treated with resection or systemic therapy alone were identified from institutional databases. Patterns of recurrence/progression and overall survival were compared using multivariable analyses of the entire cohort and a propensity score-matched cohort. Results: Of 170 patients included, 119 underwent hepatectomy and 51 received systemic treatment. Surgically treated patients had a more favourable pattern of recurrence with most recurrences limited to a single site, whereas diffuse progression was more common among patients who received systemic treatment (19 versus 44%; P = 0.002). Surgically treated patients had longer median overall survival (35 versus 20 months; P < 0.001). Hepatectomy was independently associated with better OS than systemic treatment alone (HR 0.37, 95% c.i. 0.21 to 0.65). In the propensity score-matched cohort, surgically treated patients had longer median overall survival (28 versus 20 months; P < 0.001); hepatectomy was independently associated with better overall survival (HR 0.47, 0.25 to 0.88). Conclusion: BRAF V600E mutation should not be considered a contraindication to surgery for patients with resectable, liver-only CRLMs. (© The Author(s) 2024. Published by Oxford University Press on behalf of BJS Foundation Ltd. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.) |
| References: | Eur J Surg Oncol. 2021 Nov;47(11):2722-2733. (PMID: 34099355) N Engl J Med. 2020 Dec 3;383(23):2207-2218. (PMID: 33264544) Curr Probl Cancer. 2021 Feb;45(1):100637. (PMID: 32826083) Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21. (PMID: 10493478) EBioMedicine. 2019 Feb;40:363-374. (PMID: 30733075) Ann Surg. 2004 Oct;240(4):644-57; discussion 657-8. (PMID: 15383792) Int J Cancer. 2016 Aug 1;139(3):647-56. (PMID: 26991344) World J Surg Oncol. 2022 Apr 23;20(1):131. (PMID: 35461290) Br J Cancer. 2003 Jul 21;89(2):232-8. (PMID: 12865907) Cancer. 2013 Dec 1;119(23):4137-44. (PMID: 24104864) Br J Cancer. 2015 Jun 9;112(12):1921-8. (PMID: 25942399) Br J Surg. 2019 Aug;106(9):1237-1247. (PMID: 31183866) Oncologist. 2018 Jan;23(1):128-134. (PMID: 28904173) J Clin Oncol. 2012 Aug 20;30(24):2956-62. (PMID: 22665543) Cancer Med. 2021 Oct;10(20):6998-7011. (PMID: 34535965) Ann Surg. 2022 Aug 1;276(2):357-362. (PMID: 33351476) Genome Biol. 2014 Aug 28;15(8):454. (PMID: 25164765) BMJ. 2021 Mar 29;372:n71. (PMID: 33782057) Ann Surg Oncol. 2020 Sep;27(9):3307-3315. (PMID: 32661852) Br J Surg. 2023 Jul 17;110(8):931-935. (PMID: 36511370) Oncol Rep. 2017 Feb;37(2):785-792. (PMID: 28000889) Ann Surg. 2023 Sep 1;278(3):e540-e548. (PMID: 36453261) Ann Surg. 2017 Jan;265(1):158-165. (PMID: 28009741) Ann Surg. 2020 Jan;271(1):147-154. (PMID: 29995686) Ann Surg. 2018 Jan;267(1):132-141. (PMID: 27763897) Eur J Cancer. 2019 Sep;118:121-130. (PMID: 31330487) Eur J Cancer. 2014 Jan;50(1):57-63. (PMID: 24138831) JAMA Surg. 2018 Jul 18;153(7):e180996. (PMID: 29799910) Cancer. 2017 Feb 15;123(4):568-575. (PMID: 27737491) Anticancer Res. 2018 May;38(5):2891-2895. (PMID: 29715113) J Surg Oncol. 2021 Mar;123(4):939-948. (PMID: 33400818) |
| معلومات مُعتمدة: | P30 CA008748 United States CA NCI NIH HHS; P30-CA008748 United States CA NCI NIH HHS; GR-2019-12368903 Italian Ministry of Health |
| المشرفين على المادة: | EC 2.7.11.1 (Proto-Oncogene Proteins B-raf) EC 2.7.11.1 (BRAF protein, human) |
| تواريخ الأحداث: | Date Created: 20240725 Date Completed: 20240725 Latest Revision: 20240801 |
| رمز التحديث: | 20240801 |
| مُعرف محوري في PubMed: | PMC11270119 |
| DOI: | 10.1093/bjs/znae176 |
| PMID: | 39051667 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1365-2168 |
|---|---|
| DOI: | 10.1093/bjs/znae176 |